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Abstract
New phosphorylated guanidines have been synthesized and examined as potential inhibitors for creatine kinase. These
compounds show a significant increase of inhibitory activity in comparison with the corresponding guanidines. Unlike the
X guanidines, they are competitive inhibitors because of the phosphoryl group. N-Phospho-N -2- 2,6-dichloro-
. phenyl ethylguanidine is a potent inhibitor K s2.0 mM and 1.2 mM respectively for muscle and brain-type creatinei
.kinase . Although these phosphorylated analogs of creatine phosphate have a very poor substrate activity in the reverse
reaction, the phosphoryl group is important for binding to the enzyme. q 1997 Elsevier Science B.V. All rights reserved.
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1. Introduction
Creatine kinase is a key enzyme in cellular
metabolism. The cytosolic enzyme is a dimer consist-
ing of two different subunits encoded by different
genes. These subunits can combine to form three
 .dimeric isoenzymes: CK-MM ‘muscle type’ , the
 .hybrid CK-MB ‘myocardial type’ and CK-BB
 .‘brain type’ . They catalyse the reversible transfer of
a phosphoryl group from creatine phosphate to ADP.
Abbreviations: CK, creatine kinase; CK MM, muscle type
creatine kinase; CK BB, brain type creatine kinase; CP, creatine
phosphate; Cr, creatine; PG, phosphoguanidine; K , apparents,app
dissociation constant; V , apparent maximal velocity.max,app
) Corresponding author. Fax: q33 472 110675.
In spite of more than 80% of sequence identity,
kinetic and structural differences between the two
cytosolic enzymes are evident. K for creatine phos-m
phate in muscle enzyme is 3 or 4 times higher than
w xthat of brain-type 1–3 . In the case of CK-BB, the
intrinsic dissociation constant for creatine phosphate
w xis 7 times lower than that of muscle isoenzyme 4 .
The k of brain isoenzyme in the reverse reaction iscat
3-fold lower but, approaches that of muscle enzyme
in the forward reaction. Differences in the conforma-
tional structure between the cytosolic isoenzymes
have been demonstrated by different methods —
intrinsic fluorescent intensity, anisotropic decay, ly-
sine derivatization, susceptibility to tryptic inactiva-
w xtion 5–7 . Recently, we synthesized new guanidines
with an aromatic moiety, which are good inhibitors
for both CK-MM and BB isoenzymes with a signifi-
w xcant selectivity 8 .
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w xRoberts and Walker 9 have compared the relative
activity of some creatine analogs. Among them, Cy-
 .clocreatine 1-carboxymethyl-2-iminoimidazolidine
is efficiently phosphorylated by CK to produce syn-
thetic phosphagens that are less effective than CP for
generating ATP. Recently, the importance of the
methyl group and the length of the alkyl group for
w xsubstrate activity was examined in vivo 10 . In many
cases creatine analogs are used to investigate the role
of CK in the cellular energetics. Cyclocreatine phos-
phate and phosphoguanidinopropionic acid have been
shown to accumulate in the organs of animals fed
w xcyclocreatine and guanidinopropionic acid 9,11,12 .
This accumulation induces changes in tissue CP pools
w xand in intracellular energy metabolism 13,14 . On
w xthe another hand, an anti-tumoral activity 15–17
and anti-viral effect have been associated with cy-
w xclocreatine 18 . Thus, creatine analogs may be of
interest as potential therapeutic agents.
It was therefore decided to phosphorylate our pre-
w xviously described guanidines 8 in an attempt to
obtain either more potent inhibitors or new substrates.
2. Materials and methods
2.1. Preparation of CP analogs
CP analogs were synthesized according to the
method described in detail in Appendix A.
2.2. Inhibition assay
2.2.1. Preparation of creatine kinase
Human skeletal muscle CK-MM was purchased
from Calbiochem Biochemicals. The human CK-BB
isoenzyme was prepared from human placenta fol-
w xlowing the procedure of Steghens et al. 36 .
2.2.2. Measurement of CK catalytic acti˝ities
 .Reverse reaction ATP synthesis : a hexokinase,
 .glucose-6-phosphate dehydrogenase Glc6P-DH ,
coupled assay was used to measure the inhibition by
the creatine analogs, at pH 6.6 and 378C. The final
concentrations in the assay reagent for the reverse
reaction were as follows: 2 mM NADP, 20 mM
N-acetyl-L-cysteine, 10 mM MgCl , 20 mM glucose,2
2 mM EDTA, 3 Urml hexokinase, 2 Urml Glc6P-
DH, creatine phosphate or ADP at different concen-
trations as starting reagent. Each catalytic activity
measurement was made in triplicate on a centrifuge
 .analyser Monarch, Instrument Laboratory . The CK
enzyme was preincubated with or without creatine
phosphate analogs 5a or 5b for five minutes before
the start of the measurement with creatine phosphate
or ADP.
 .Forward reaction creatine phosphate formation :
A pyruvate kinase, lactate dehydrogenase, coupled
assay was used to measure the inhibition activity of
the analogs, at pH 8.8 and 378C. The final concentra-
tions in the assay reagent were as follows: 4 mM
ATP, 0.25 mM NADH, 4 mM MgCl , 0.4 mM2
phosphoenolpyruvate, 10 mM dithiothreitol, 5.6
Urml pyruvate kinase, 10 Urml L-lactate dehydro-
genase, creatine or ATP at different concentrations as
starting reagent.
2.2.3. Creatine phosphate analogs as substrates
In the same coupled assay as for reverse reaction,
creatine phosphate analogs replaced creatine phos-
phate as starting reagent.
2.2.4. Determination of K ˝aluesi
Inhibition constants were determined from initial
rate measurements made at different substrate con-
centrations creatine phosphate, creatine, ADP, or
.ATP in the presence of varied inhibitor concentra-
 .tions. The K rV slope was determineds,app max,app
w xfrom a plot of 1r˝ vs. 1r S and used for the
graphical evaluation of K from a plot of the slopei
versus inhibitor concentration.
2.3. Equilibrium constant
The equilibrium constant of the reaction, CPq
guanidinemCrqphosphoguanidine, was measured
according to the method described by Annesley and
w x  .Walker 19 . 3 mgrml 1500 Urml of CK is used.
After incubation for 12 h at 308C, pH 6.6, the
reaction mixture was separated by capillary elec-
 .trophoresis Kontron, Eureka 2100 system with UV
detection. The reactant concentrations were measured
by peak area integration versus standards. The runs
were performed under the following conditions: 258C,
ls205 nm, Vs15 kV, 50 mM NaH PO buffer,2 4
pH 7.0. A 75 mm diameter and 40 cm length to the
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.detector fused silica capillary column was used.
3. Results
3.1. Synthesis
The route used for the synthesis of phosphorylated
guanidine derivatives 5 is outlined in Fig. 1. The
dibenzylphosphoguanidine derivatives, 4a and 4b
were prepared by acting N-dibenzylphos-
phorylcyanamide 2 on the appropriate amine hydro-
w xchlorides 3 described by Min et al. 8 . The benzyl
groups were then removed by hydrogenolysis using
platinum oxide as the catalyst. This route is quite
similar to that reported by Cramer and Vollmar
w x20,21 , except that we used the dibenzyl compound 2
instead of di-p-nitrobenzyl and that, for its prepara-
tion, the reaction mixture was sonicated instead of
w xvibrated. Our previous results 8 had shown that
 .3- 2,6-dichlorophenyl propylguanidine was very ac-
 .tive on CK-BB K s4.4 mM . Thus we tried toi
synthesize the corresponding phosphorylated com-
X pound. N-Dibenzylphospho-N -3- 2,6-dichloro-
.phenyl -propylguanidine was prepared by the method
described in Fig. 1. Unfortunately, the hydrogenoly-
sis of the benzyl groups proved to be problematic in
this case. Using platinum oxide as the catalyst, the
deprotection was incomplete, giving rise to a mixture
of monodebenzylated and starting compound, even
after 12 h of reaction. When we used 5% palladium
on charcoal as catalyst, the two benzyl groups were
removed in a few minutes, but we obtained a mixture
consisting mainly of dechlorinated compounds be-
sides a small amount of the desired one as shown by
1 .H-NMR . In order to obtain crystalline solids, 5a,b
 .were isolated respectively as their mono 6a or
 .disodium 6b salts.
3.2. Enzymatic results
These new creatine phosphate analogs were tested
as inhibitors for creatine kinase. Typical plots of
X  .inhibition for N-phospho-N -2- 2,6-dichlorophenyl -
 .ethylguanidine 5b versus creatine phosphate are
given in Fig. 2. In the reverse direction ATP forma-
.tion , the two phosphorylated analogs are competitive
inhibitors with respect to creatine phosphate and
 .mixed-type inhibitors with respect to ADP Table 1 .
K values of the analog 5b vs. creatine phosphate arei
2.0 and 1.2 mM respectively for CK-MM and BB,
and comparable, for CK-MM, to 1-carboxymethyl-2-
 .iminoimidazolidin-4-one K s2 mM reported byi
w xLeyh et al. 22 . With respect to ADP, the K valuesi
for the two analogs are very similar for the two
isoenzymes.
In the forward reaction creatine phosphate synthe-
.sis , the inhibitors are noncompetitive with respect to
 .  .  .Fig. 1. Synthetic scheme for preparation of the phosphorylated analogs.: a dibenzyl-phosphiterNaOHPCCl ; b HgOrNa CO ; 3 3,4 2 3
 .  .isobutanol; d H rPtO cat.rmethanol; e NaOMe, MeOH.2 2
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Table 1
 .Kinetic constants for reverse reaction ATP formation with cytosolic creatine kinases
aIsoenzyme Substrate varied K Analog 5a Analog 5bm
K Inhibition type K Inhibition typei i
mM mM mM
CK-MM CP 2.38 4.2"0.4 C 2.0"0.7 C
ADP 0.13 12.0"0.2 MT 10.0"0.1 MT
CK-BB CP 0.66 4.9"0.2 C 1.2"0.5 C
ADP 0.07 12.3"0.3 MT 7.0"0.3 MT
a w xK values from Steghens et al. 36 .m
The abbreviation is C, competitive inhibition; MT, mixed-type inhibition.
Table 2
 .Kinetic constants for forward reaction CP formation with cytosolic creatine kinases
Isoenzyme Substrate varied K Analog 5a Analog 5bm
K Inhibition type K Inhibition typei i
mM mM mM
CK-MM Cr 24.3 13 "0.2 NC 8.3"0.3 NC
ATP 1.4 12.5"0.4 C 5.0"0.4 C
CK-BB Cr 9.7 9.5"0.3 NC 6.6"0.2 NC
ATP 1.1 14.5"0.5 C 4.6"0.1 C
Abbreviations: C, competitive inhibition; NC, noncompetitive inhibition.
creatine and mixed-type with respect to ATP Table
.2 . Between the two isoenzymes, the K values arei
of the same order of magnitude and higher than in the
reverse reaction.
These K values are compared with that of creati-i
nine phosphate and the parent guanidines in Table 3.
The new phosphorylated compounds show an en-
hancement of inhibitory activity, an up to 20-fold
increase of K in comparison with the parent guani-i
dines. They both act as strictly competitive inhibitors
with respect to creatine phosphate whereas the corre-
sponding guanidines were mixed-type inhibitors. Thus
the phosphorylation of the guanidines induces not
only a dramatic increase in inhibition but also a
decrease in its enzyme specificity.
 .When these analogs 5a and 5b were investigated
Table 3
Comparison of the apparent affinities of creatine phosphate analogs
Analogs K fori
CK-MM CK-BB
mM mM
aCreatinine phosphate 5
b b2,6-Dichlorobenzylguanidine 5.2"0.8 44.3"5.3
b b .2- 2,6-Dichlorophenyl ethylguanidine 42.3"3.1 23.4"4.1
X  .N-Phospho-N -2,6-dichlorobenzylguanidine 5a 4.2"0.4 4.9"0.7
X  .  .N-Phospho-N -2- 2,6-dichlorophenyl ethylguanidine 5b 2.0"0.2 1.2"0.5
a w xFrom 31 , pH 7.0 at 308C.
b w xFrom 8 , pH 6.6 at 378C.
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X Fig. 2. Inhibition of CK by N-phospho-N -2- 2,6-dichloro-
.  .phenyl ethylguanidine with creatine phosphate as substrate: A
 .CK-MM; B CK-BB. Double reciprocal plots of velocity versus
substrate concentration. Inhibitor concentrations were as follows:
 .  .  .  .0 ‘ ; 0.5 v , 1 ^ ; 2 % mM.
for substrate activity in the reverse reaction, we were
not able to detect any ATP formation in the usual
measurement conditions approximately 1000 Url at
.378C . These analogs only were extremely poor sub-
 .strates 100 000 times less reactive than CP for
cytosolic CK.
The apparent equilibrium constant is determined in
the presence of CK and a small amount of ATP. The
apparent equilibrium constant measurement showed
the variation of free enthalpy during the phosphate
 .group hydrolysis from phosphoguanidine 5b to be
only 1 kcalrmol lower than that of CP y10.8
w x.kcalrmol, 23 .
4. Discussion
Given that the previously described creatine
analogs showed a mixed-type inhibitory activity and
some isoenzyme specificity between CK-MM and
w xCK-BB 8 , the corresponding phosphorylated deriva-
tives were prepared and tested. These compounds are
strict competitive inhibitors and are more potent than
the non-phosphorylated ones. To our knowledge, the
dichloro compound 5b is the most potent inhibitor
 .ever described for CK BB K s1.2 mM .i
On the one hand, these results show that, for both
 .CK-MM and CK-BB, 1 the phosphoryl group is
 .essential for this type of inhibition, 2 this group
increases the inhibitory activity of each compound,
 .3 by comparison with the parent guanidines, the
affinity of this group for the catalytic site is larger
than that of the aromatic moiety. On the other hand,
as already observed with these guanidines for CK-BB,
it seems that the longer the apparent distance between
the dichloro-aromatic and phosphoguanidine groups,
the more potent the inhibitor. This criterion of ‘ap-
parent distance’ may be a specific feature of CK-BB.
The phosphorylation of the guanidines has only a
weak effect for CK-MM. On the contrary, the same
 .phosphorylation induces a systematic 10 5a –20
 .5b -fold increase in the inhibitory activity for CK-BB
in the reverse reaction. Thus, it is plausible to con-
clude that only CK-BB is able to sum up two binding
effects one for the phosphoryl group and the other
.for the aromatic moiety resulting in the dramatic
enhancement of inhibition observed. The ‘long’ alkyl
chain of 5b may facilitate this cumulative effect by
its relative flexibility.
Another explication could be that the binding of
the phosphoryl group induces a conformational
change of the enzyme and therefore decreases the
affinity for the aromatic moiety of our new analogs.
This induced fit phenomenon has been already de-
w xscribed for some kinases 24 . Even if they differ in
primary structures, these kinases have a very similar
cleft of two lobes containing the active site. This
common structure allows, for instance, the conforma-
tional changes on substrate binding and catalysis in
w xthe case of hexokinase 25–27 . The induced confor-
mational change favors the increase of affinity for the
other substrate in the cleft. In the case of CK-MM,
there is no evidence in substrate-dependent conforma-
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tional changes. Only for CK-BB, pH-related and
substrate-induced conformational changes in the
w xternary complex may be considered 28 .
The simplest way to explain the different inhibi-
tion patterns is to consider the formation of dead-end
complexes. It is well known that E-MgADP-Cr com-
plex is stabilized by planar anions such as nitrate.
Nitrate can replace phosphate in the complex which
mimics the transition-state analog, E-MgADP-Pi-Cr
w x 29,30 . In the reverse reaction, both complexes E-
.PG, E-PG-MgADP can lead to competitive inhibi-
tion vs. CP and mixed-type inhibition versus ADP. In
the forward direction, E-PG is the only possible
complex. In this case, according to the results in
Table 2, the inhibition is competitive with respect to
ATP and noncompetitive with respect to creatine.
Finally, the question arises why these molecules
with a potential phosphoryl group transfer are very
poor substrates. This could be due to the absence of
the carboxyl moiety as observed by Gercken and
w xDoring 31 with the creatinine phosphate, which is¨
an inhibitor but not a substrate. The influence of this
group has been hypothetized to be important for the
steric orientation and activation of the phosphoryl
w xgroup 32 . Another reason could be the lack of the
N-methyl group: according to James and Morrison
w x33 , it has an essential role in the interaction between
the guanidino compound and the nucleotide in the
binding site of the enzyme. It is also known that the
V for the phosphorylated derivative of b-max
guanidinopropionic acid is less than 0.1% that of
w xcreatine phosphate 34 and the phosphorylated 1-
carboxymethyl-2-iminoimidazolidine reported as a
substrate for creatine kinase is in fact poor 0.6%
. w xV compared to creatine phosphate 35 . Even if,max
from an energetical point of view, PG could poten-
tially be good substrates, they lack a methyl group or
a carboxyl group that might prevent CK from
catalysing the phosphoryl group transfer.
We have checked in vitro that dichloroaromatic
guanidines, either phosphorylated or not, are more
specific for CK-BB than the previous known analogs
 .guanidinoacetic acid, guanidinopropionic acid, etc .
Given that phosphoguanidinoacetic acid is a better
substrate for CK-BB V rK at pH 6.6, personalmax m
.results , the difference in specificity of our new
compounds relies on the dichloroaromatic moiety. If
these new guanidines can be also phosphorylated
slowly in vivo, it is hopeful we will obtain a potent,
selective inhibition with the CK-BB rich cells.
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Appendix A. Chemical synthesis
( )A.1. N-Dibenzylphospho-S-methyl-isourea 1
To a suspension of S-methyl-iso-thiouronium sul-
 .fate 7 g; 5 mmol in 50 ml of carbon tetrachloride,
 .was added 13.1 g 5 mmol of dibenzylphosphite in
50 ml of carbon tetrachloride. A solution of 4 g of
NaOH in 12 ml of H O was then added dropwise at2
08C and the mixture was stirred for 2 h at room
temperature. The organic phase was washed succes-
sively with 20 ml of 10% sulfuric acid, 10% NaHCO3
 .solution 2=30 ml , dried and concentrated. The
white solid thus obtained was triturated with pentane
 . and filtered to yield 11.5 g 65% of 1. m.p. 888C lit.
. 1  .898C; Cramer and Vollmar, 1958 ; H-NMR CDCl3
 .  3 . d 7.33 m, 12H , 5.02 d, J s8.1 Hz, 4H , 2.28 s,HP
.3H . The calculated analytical composition for
C H NPO S is as follows: C, 54.85; H, 5.47;16 19 3
found: C, 54.74; H, 5.51.
( )A.2. N-Dibenzylphosphorylcyanamide sodium salt 2
 .To a solution of 3.5 g 10 mmol of compound 1
in 90 ml of ethanol, was added a solution of 1.3 g of
HgO and 0.6 g of Na CO in 20 ml of H O. The2 3 2
mixture was sonicated for 2 h at 608C and, after a
further addition of 1.3 g HgO, sonicated for addi-
tional 3 h at the same temperature and was finally
allowed to stand overnight. After filtration and con-
 .centration, we thus obtained 2.63 g 81% of crude
oily product 2 which was used without purification.
A.3. General procedure for phosphorylation
A equimolar solution of appropriate amine hydro-
chloride 3 and compound 2 in isobutanol was re-
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fluxed with stirring for 1 h. The solution was concen-
trated and, after addition of water, the reaction mix-
ture was extracted with dichloromethane. The organic
phase was dried and concentrated. The crude product
4 thus obtained was purified by silica chromatogra-
w  . xphy eluent: 98: 2 by vol. ethyl acetatermethanol .
N-Dibenzylphospho-N X-2,6-dichlorobenzylguani-
( )  .dine 4a : From 1.5 g 5.7 mmol of 2,6-dichloroben-
 .zylamine hydrochloride we obtained 1.35 g 50% of
compound 3a. IR 3420, 3320, 1615, 1555, 1435,film
y1 1  .  .1020 cm ; H-NMR CDCl d 7.31 m, 12H , 7.053
 .  . m, 1H , 6.0 M, 2H exchangeable D O , 4.94 d,23 .  . J s7.8 Hz, 4H , 4.65 d, Js5.5 Hz, 2H , 1.7 m,HP
.broad s, 1H exchangeable D O . The calculated ana-2
lytical composition for C H Cl N PO is as fol-22 22 2 3 3
lows: C, 55.24; N, 8.78; Cl, 14.82; P, 6.48. found: C,
55.55; N, 8.52; Cl, 14.59; P, 6.21.
X ( )N-Dibenzylphospho-N -2- 2,6-dichlorophenyl -
( )  .ethylguanidine 4b : From 1.0 g 3.6 mmol of 2,6-
dichlorophenylethylamine hydrochloride we obtained
 .0.82 g 48% of compound 4b. IR 3440, 3340,film
y1 1  .1625, 1570, 1435, 1015 cm ; H-NMR CDCl d3
 .  . 7.33 m, 12H , 7.27 m, 1H , 6.00 M, 2H exchange-
.  3 .  .able D O , 4.96 d, J s7.3Hz, 4H , 3.40 m, 2H ,2 HP
 .  .3.15 m, 2H , 1.75 broad s, 1H exchangeable D O .2
The calculated analytical composition for
C H Cl N PO is as follows: C, 56.11; N, 8.53;23 24 2 3 3
Cl, 14.40; P, 6.29. found: C, 55.95; N, 8.38; Cl,
14.13; P, 6.03.
( )A.4. Sodium salts of N-phosphoguanidine 5
A solution of dibenzylated phosphoguanidines 4 in
50 ml of methanol were submitted to an atmospheric
pressure of hydrogen in the presence of a catalytic
amount of platinium oxide for 5 h. The catalyst was
then filtered off and the solvent evaporated. A
methanolic solution of crude phosphoguanidine 5
 .thus obtained was treated by 1 or 2 mol. of a 0.3 M
sodium methoxide in methanol. The monosodium salt
6a or disodium salt 6b were precipitated from the
above solution by addition of diethyl ether, filtered
and dried in vacuo. They were obtained as a hygro-
scopic powder.
N-Phospho-N X-2,6-dichlorobenzylguanidine
( )  .sodium salt 6a : From 1.3 g 2.7 mmol of 4a we
 . 1obtained 0.62 g 73% of compound 6a. H-NMR
 .  .  .D O d 7.5–7.2 m, 3H , 4.70 s, 2H . The calcu-2
lated analytical composition for C H Cl N PO PNa8 9 2 3 3
PH O is as follows: C, 28.42; H, 3.28; N, 12.42; Cl,2
20.70; P, 9.16. found: C, 28.40; H, 3.24; N, 12.65;
Cl, 20.82; P, 9.32.
X ( )N -P h o sp h o -N -2 - 2 ,6 -d ic h lo ro p h e n y l -
( ) ethylguanidine disodium salt 6b : From 1.24 g 2.5
.  .mmol of 5b we obtained 0.72 g 79% of compound
1  .  .  .6b. H-NMR D O d 7.42 m, 2H , 7.24 m, 1H ,2
 .  .3.50 m, 2H , 3.25 m, 2H . The calculated analytical
composition for C H Cl N PO PNa P3H O is as9 10 2 3 3 2 2
follows: C, 26.36; H, 3.93; N, 10.25; Cl, 17.29; P,
7.55; Na, 11.21. found: C, 26.69; H, 3.84; N, 10.22;
Cl, 17.28; P, 7.34; Na, 10.95.
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